$BEAT

HeartBeam, Inc. (BEAT): Submission of Matters to a Vote of Security Holders

HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On July 31, 2026, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast. As of the close of business on June 5, 2026, the record date for the Annual M

Original reporting
Published Aug 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BEAT
Neutral
medium confidence
Mentioned
$BEAT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BEATNeutralLow
01

Why it matters

Director nominees were elected and the independent auditor ratification passed, while the proposal to amend the 2022 Equity Incentive Plan to add 3,000,000 authorized shares was not approved.

02

Market read

Traders may monitor whether the failed equity plan amendment leads to a resubmission or alternative compensation approach, but the filing itself is not a fundamental catalyst.

03

What to watch

The filing does not state whether the company will resubmit the proposal, adjust the plan, or pursue alternative equity compensation structures, so the practical impact may be smaller than the vote result suggests.

Relevance 6/10Novelty 2/10Timing: after-hours filing of July 31 annual meeting vote results (filed Aug 3, 2026)

Background

This is an SEC Form 8-K under Item 5.07 summarizing matters voted on at HeartBeam’s annual meeting held virtually on July 31, 2026.

Company-level read

Ticker impact

$BEATNeutralMedium confidence
Context

HeartBeam filed an 8-K reporting the results of its July 31, 2026 annual meeting, including director elections and a failed equity plan amendment.

Expected impact

Likely limited near-term impact; any reaction would be second-order and depends on how investors view the failed plan amendment.

Evidence & confidence

8-K Item 5.07 discloses vote tallies. It does not include new financial guidance, transactions, or regulatory outcomes. The failed proposal could affect future compensation flexibility, but the article provides no follow-on actions or timeline.

Market effects

Minimal. Governance vote outcomes are not typically sector-moving without accompanying financing, restructuring, or regulatory developments.

Minimal.

Minimal.

Counterpoint

The failed equity plan amendment could signal shareholder resistance to dilution, which may constrain future hiring/retention plans and indirectly pressure sentiment if compensation needs are urgent.

Key entities

  • HeartBeam, Inc.

    NASDAQ-listed company whose annual meeting vote results are reported in the 8-K.

  • CBIZ CPAs P.C.

    Independent registered public accounting firm whose appointment was ratified for fiscal year ending Dec. 31, 2026.

Related articles

$BEATMed

HeartBeam gains FDA acceptance into device acceleration program

HeartBeam (NASDAQ:BEAT) announced FDA acceptance into its Total Product Life Cycle Advisory Program Pilot for its 3D ECG technology, aiming to accelerate access for heart attack assessment. The company received FDA Breakthrough Device Designation earlier this month and plans to begin patient enrollment in Q1 2027. The program provides regulatory support and connects developers with healthcare stakeholders.

$BEATMed

Heart attack assessment technology reaches two FDA milestones in under a month.

HeartBeam (NASDAQ: BEAT) announced its heart attack assessment technology was accepted into the FDA's TAP Pilot program, following a Breakthrough Device Designation earlier this month. The TAP program offers regulatory support and early engagement with payers. The company aims to begin patient enrollment for a pivotal study in Q1 2027, pending FDA alignment. The HeartBeam System is currently cleared for arrhythmia assessment but not for heart attack detection.

$BEATLow

HeartBeam, Inc. (BEAT) Completes Enrollment of 486-Patient ACS Study

HeartBeam, Inc. (BEAT) has finished enrolling 486 patients in the HEADSTART-ACS study for its 3D ECG device, with data analysis ongoing and results expected in 2027. The device is not yet cleared for heart attack detection. According to the company, this study aims to expand clinical evidence after prior arrhythmia-focused clearances.

$BEATMed

486 patients enrolled ahead of schedule in HeartBeam’s largest heart attack detection study.

HeartBeam Inc. (NASDAQ: BEAT) completed enrollment in its HEADSTART-ACS study, evaluating its 3D ECG system for heart attack detection, ahead of schedule. The study, conducted with Indonesia's National Cardiovascular Center, enrolled 486 patients. Results are expected in 2027. The company has over 600 patients in its heart attack detection studies, ahead of its U.S. pivotal study planned for Q1 2027.

$BEATMedAI 8/10

Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news

H.C. Wainwright maintained a Neutral rating on Heartbeam Inc. (BEAT) after its HeartBeam System received FDA Breakthrough Device designation. The stock rose 78% to $0.65, with a market cap of $36.86M. The designation, based on ALIGN-ACS study data, expedites Medicare coverage. BEAT reported a Q2 EPS of -$1.10, missing estimates by $1.01, and plans a $25M equity offering.